Diagnosing and Managing Blastic Plasmacytoid Dendritic Cell Neoplasm: A Hematological Malignancy with Inaugural Skin Manifestations

CME Activities

Linking Inaugural Skin Manifestations With BPDCN: Clinical Pearls for Identification and Management 

Medscape Education, June 2022

Did you know that blastic plasmacytoid dendritic cell neoplasm (BPDCN) is not as rare as previously thought?

0.50 CME
A Hematologic Malignancy With Inaugural Skin Manifestations: Test Your Knowledge

Medscape Education, April 2022

Did you know of targeted therapies improving outcomes for patients with rare hematologic malignancies presenting with skin manifestations?

0.25 CME

BPDCN and Skin Manifestations

What You Need to Know About A Hematologic Malignancy With Inaugural Skin Manifestations

Resources

Downloadable Slide Kit

Clinical Advances in Diagnosing and Managing Blastic Plasmacytoid Dendritic Cell Neoplasm: A Hematological Malignancy with Inaugural Skin Manifestations

Clinical References

Steering Committee

Eric Deconinck, MD, PhD

Steering Committee Chair

Professor of Hematology
Hospital Jean Minjoz
Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, RIGHT
Service d'hématologie Clinique, Centre Hospitalier Universitaire de Besançon
Besançon, France

Bio Video

Emanuele Angelucci, MD

Professor
Head, Hematology and Transplant Unit
IRCCS Ospedale Policlinico San Martino
Genova, Italy

Bio Video

Marco Herling, MD

Head of Lymphoma and Cell Therapy Program
Department of Hematology, Cellular Therapy, and Hemostaseology
University of Leipzig
Leipzig, Germany

Pau Montesinos, MD, PhD

Hospital Universitari i Politécnic La Fe
Valencia, Spain

Bio Video

Livio Pagano, MD

Associated Professor of Hematology
Director of Geriatric Hematology and Rare Hemopathies Division
Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia
Fondazione Policlinico Universitario A. Gemelli - IRCCS - Università Cattolica del Sacro Cuore
Rome, Italy

Bio Video

Naveen Pemmaraju, MD

Associate Professor
Director, Blastic Plasmacytoid Dendritic Cell Neoplasm Program
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas, United States

Daniel Wiseman, MD, ChB, PhD

Consultant Haematologist
The Christie NHS Foundation Trust
Manchester, United Kingdom

Bio Video

Steering Committee

Eric Deconinck, MD, PhD

Steering Committee Chair

Disclosure: Eric Deconinck, MD, PhD, has the following relevant financial relationships:

Served as an advisor or consultant for: Immunogen; Menarini; Stemline

Served as a speaker or a member of a speakers bureau for: Menarini; Stemline

Received grants for clinical research from: Chugai; Gilead; Novartis; Pfizer

Emanuele Angelucci, MD

Steering Committee Member

Disclosure: Emanuele Angelucci, MD, has no relevant financial relationships.

Marco Herling, MD

Steering Committee Member

Disclosure: Marco Herling, MD, has no relevant financial relationships.

Pau Montesinos, MD, PhD

Steering Committee Member

Disclosure: Pau Montesinos, MD, PhD, has no relevant financial relationships.

Livio Pagano, MD

Steering Committee Member

Disclosure: Livio Pagano, MD, has the following relevant financial relationships:

Served as an advisor or consultant for: Blueprint; Cidara; Gilead; Menarini

Served as a speaker or a member of a speakers bureau for: Gilead; Janssen; Jazz; Novartis; Pfizer

Received grants for clinical research from: Gilead

Naveen Pemmaraju, MD

Steering Committee Member

Disclosure: Naveen Pemmaraju, MD, has the following relevant financial relationships:

Served as an advisor or consultant for: AbbVie; Aptitude Health; Astellas; Bristol Myers Squibb Company; Cimeio; ClearView; CTI Biopharma; Incyte; Intellisphere; Novartis AH; Novartis; Patient Power; PharmaEssentia; Protagonist; Stemline

Served as a speaker or a member of a speakers bureau for: AbbVie; Curio; Dava; Magdalen; Stemline

Received grants for clinical research from: AbbVie; Ascentage; Cellectis; Daiichi Sankyo; MustangBio; Novartis; Plexxikon; Rafael; SagerStrong; Samus; Stemline

Daniel Wiseman, MD, ChB, PhD

Steering Committee Member

Disclosure: Daniel Wiseman, MD, ChB, PhD, has the following relevant financial relationships:

Served as an advisor or consultant for: Novartis; Stemline

Served as a speaker or a member of a speakers bureau for: Janssen; Novartis

Received grants for clinical research from: Astex